Crocs (NASDAQ:CROX) Releases Q2 2026 Earnings Guidance

Crocs (NASDAQ:CROX) issued an update on its second quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.150-4.350 for the period, compared to the consensus estimate of 4.300. The company issued revenue guidance of -, compared to the consensus revenue estimate of $1.1 billion. Crocs also updated its FY 2026 guidance to 13.200-13.750 EPS.

Crocs Price Performance

NASDAQ:CROX opened at $103.88 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.74 and a current ratio of 1.67. The stock’s 50-day simple moving average is $90.70 and its 200 day simple moving average is $87.11. The company has a market cap of $5.20 billion, a P/E ratio of -82.44, a P/E/G ratio of 1.19 and a beta of 1.54. Crocs has a 52-week low of $73.21 and a 52-week high of $122.84.

Crocs (NASDAQ:CROX) last released its earnings results on Thursday, April 30th. The textile maker reported $2.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.78 by $0.21. The business had revenue of $921.46 million for the quarter, compared to the consensus estimate of $900.57 million. Crocs had a positive return on equity of 48.29% and a negative net margin of 2.58%.Crocs’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.00 earnings per share. Crocs has set its Q2 2026 guidance at 4.150-4.350 EPS and its FY 2026 guidance at 13.200-13.750 EPS. As a group, sell-side analysts forecast that Crocs will post 13.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CROX has been the topic of a number of recent research reports. BTIG Research began coverage on Crocs in a research report on Tuesday, March 10th. They issued a “neutral” rating on the stock. UBS Group boosted their price target on Crocs from $97.00 to $107.00 and gave the stock a “neutral” rating in a research report on Friday. Seaport Research Partners raised Crocs from a “neutral” rating to a “buy” rating and set a $135.00 price target on the stock in a research report on Tuesday, April 14th. Weiss Ratings downgraded Crocs from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, February 23rd. Finally, Wall Street Zen raised Crocs from a “hold” rating to a “buy” rating in a research report on Saturday, April 11th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $103.73.

Insiders Place Their Bets

In other Crocs news, EVP Anne Mehlman sold 12,145 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $100.06, for a total transaction of $1,215,228.70. Following the transaction, the executive vice president owned 131,112 shares of the company’s stock, valued at $13,119,066.72. The trade was a 8.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.00% of the stock is currently owned by company insiders.

Crocs News Roundup

Here are the key news stories impacting Crocs this week:

• Positive Sentiment: Crocs beat Q1 expectations — EPS $2.99 vs. $2.78 consensus and revenue $921.5M vs. $900.6M — and raised its full?year outlook, citing healthy DTC growth that supports higher margin expectations. Crocs, Inc. Reports Better-Than-Expected First Quarter 2026 Results And Raises Full-Year Outlook
• Positive Sentiment: Management highlighted DTC revenue growth (+12% y/y) that helped drive the beat and prompted a lift to FY EPS guidance (now 13.20–13.75), which reassures investors on margin recovery and topline stability. Crocs Q1 Earnings Beat Estimates on DTC Growth, View Raised
• Neutral Sentiment: UBS raised its price target to $107 (from $97) but kept a “neutral” rating — signaling improved valuation but not an upgrade in conviction. This provides some analyst support but limited catalyst. UBS Adjusts Price Target on Crocs to $107 from $97, Maintains Neutral Rating
• Neutral Sentiment: Other brokerage target updates cluster around the low?$100s (median targets near current levels), suggesting consensus expectations are close to the current trading price. Brokerages Set Crocs, Inc. (NASDAQ:CROX) Target Price at $102.73
• Neutral Sentiment: Crocs published its 2025 Comfort Report (sustainability & purpose updates). This bolsters long?term brand positioning but is unlikely to move near?term earnings expectations. Crocs, Inc. Publishes 2025 Comfort Report Detailing Updates on Purpose & Sustainability
• Negative Sentiment: Some coverage noted intraday weakness as investors focused on soft spots: management flagged HEYDUDE brand pressure and Q2 EPS guidance that sits near (or slightly below) consensus, prompting profit?taking despite the beat. Why Is Crocs Stock Falling Thursday?
• Negative Sentiment: Additional reports highlighted shares dipping on the Q2 outlook and specific category weakness, a reminder that topline is still showing pockets of softness even as margins improve. Crocs Inc CROX Q1 earnings shares down on Q2 outlook

Hedge Funds Weigh In On Crocs

Several institutional investors and hedge funds have recently made changes to their positions in CROX. AQR Capital Management LLC grew its position in shares of Crocs by 399.0% in the third quarter. AQR Capital Management LLC now owns 1,266,799 shares of the textile maker’s stock valued at $105,841,000 after purchasing an additional 1,012,943 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its position in shares of Crocs by 78.7% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 907,988 shares of the textile maker’s stock valued at $77,651,000 after purchasing an additional 399,964 shares during the last quarter. Incision Capital Management LP acquired a new position in shares of Crocs in the fourth quarter valued at approximately $27,794,000. Patient Capital Management LLC grew its position in shares of Crocs by 28.9% in the fourth quarter. Patient Capital Management LLC now owns 758,797 shares of the textile maker’s stock valued at $64,892,000 after purchasing an additional 170,003 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Crocs by 1,171.9% in the third quarter. Two Sigma Investments LP now owns 162,040 shares of the textile maker’s stock valued at $13,538,000 after purchasing an additional 149,300 shares during the last quarter. Institutional investors and hedge funds own 93.44% of the company’s stock.

About Crocs

Crocs, Inc is a global footwear designer, developer and distributor best known for its lightweight, proprietary Croslite™ foam-clog construction. The company’s product portfolio encompasses a range of styles, including clogs, sandals, slides, boots and sneakers, all featuring the slip-resistant, odor-resistant and cushion-providing qualities of the Croslite material. Crocs distributes its products through an omnichannel network that includes e-commerce platforms, company-owned retail stores, authorized dealers and wholesale partners.

Founded in 2002 by Scott Seamans, Lyndon “Duke” Hanson and George Boedecker Jr., Crocs launched its first clog on the island of Vail, Colorado.